Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

CRISPR Therapeutics AG (NASDAQ:CRSP) shares declined 6.75% on Tuesday after the company revealed plans to raise $350 million through a convertible senior notes offering. The gene-editing firm said it ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 17, Morgan Stanley increased its price target on CRISPR Therapeutics AG ...

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

CRISPR THERAPEUTICS ® standard character mark and design logo and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY ® and the CASGEVY logo are registered trademarks ...

The gene-editing company said it intends to offer the convertible senior notes due 2031 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The ...

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

Shares of Crispr Therapeutics were lower after the company said it would raise $350 million through a private offering of senior notes. The stock was down 7.3% at $54.49 in Tuesday morning trading.

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value ...

Discover how CRISPR-based therapy could revolutionize HPAI treatment in poultry, offering farmers a lifesaving alternative to complete flock depopulation and preventing costly outbreaks.